Various countries report development in Covid-19 vaccine trials
Various countries have recently reported good development within their Covid-19 vaccine clinical trials, bringing a desire to the world through the precarious Coronavirus situation.
Besides, the health specialists called for a target, rational and scientific attitude towards vaccine candidates, said a report of Xinhua on Wednesday.
According to data introduced by the World Health Organization (WHO) on Monday, it is said that at least 24 COVID-19 applicant vaccines are in clinical evaluation, and another 142 in preclinical evaluation.
On Mon alone, four countries reported their brand-new research benefits of COVID-19 vaccines.
Chinese specialists said in a fresh study published on medical journal The Lancet a phase 2 trial of a COVID-19 vaccine prospect has discovered that the vaccine is secure and induces an immune response.
"The phase 2 trial adds further evidence about safety and immunogenicity in a large population than the phase 1 trial. That is an important part of evaluating this early-level experimental vaccine and period 3 trials are now underway," explained Professor Fengcai Zhu from Jiangsu Provincial Centre for Disease Control and Prevention, China.
A written report published also in The Lancet reveals the benefits of the period 1/2 trial of the Oxford coronavirus vaccine ChAdOx1 nCoV-19.
This implies no early safety worries and produces strong immune response.
Based on the University of Oxford, the trial consists of a lot more than 1,000 healthy adult volunteers. The vaccine provoked a T cell response (white blood cells that may assault cells infected with the SARS-CoV-2 virus) within 2 weeks of vaccination, and an antibody response within 28 days.
The Russian Defense Ministry said that together with the Gamaleya Scientific Exploration Institute of Epidemiology and Microbiology, it has successfully completed clinical trials of COVID-19 vaccine with the participation of volunteers.
"Without exception, all volunteers, having received immunity from the coronavirus, felt great," Earliest Deputy Defense Minister of the Russian Federation Ruslan Khadzhismelovich Tsaikov advised Moscow's Argumenty we Fakty newspaper.
German biotech firm BioNTech and U.S. pharmaceutical company Pfizer announced that data from their experimental COVID-19 vaccine confirmed that it was safe, and induced an immune response and high-level T-cell responses against the novel coronavirus in patients.
Earlier this month, exploration institutes in other countries also reported progress within their COVID-19 vaccine trials.
In a report published July 14 in the brand new England Journal of Medicine, researchers reported that the COVID-19 vaccine mRNA-1273, co-developed by the U.S. National Institute of Allergy and Infectious Diseases and U.S. biotech organization Moderna Therapeutics, induced immune responses and no serious unwanted effects in volunteers in the next clinical trial.
Additionally, the University of Queensland in Australia, Chulalongkorn University found in Thailand, among other institutes, also reported excellent results within their COVID-19 vaccine research.
Despite the very good news on COVID-19 applicant vaccines, professionals warned of uncertainties of vaccine development and scientific trials, along with multiple risks and issues including virus mutation, while appealing for an objective, rational and scientific attitude towards vaccine study.
Dr Michael Ryan, executive director of the WHO Health Emergencies Method, said on July 3 that there surely is zero accurate timetable for the delivery of COVID-19 vaccines.
Although the preliminary data of plenty of candidate vaccines is pretty promising, it is still unpredictable which is completely clinically effective, he told a briefing.
While a vaccine candidate might show its effectiveness by year's end, the question is how in the near future it could be produced in higher quantities, he added.
Saudi Arabia's Asharq al-Awsat newspaper said recently that researchers should don't be over-optimistic about the significant progress of some candidate vaccines in medical trials, and wait for further trial results.
Merck CEO Kenneth Frazier said that the potency of developing vaccines can't be guaranteed.
Some analyses showed that the amount of anti-bodies will decline after COVID-19 patients recover. Joint attempts of scientific research teams are needed to tackle concerns including how COVID-19 vaccines provide satisfactory long-term immunity and how exactly to cope with possible virus variation.
The WHO urged that before a COVID-19 vaccine is officially available, all countries should constantly take full-flung prevention and control measures.
